retatrutide efficacy clinical trials New Phase 3 data just dropped 👀 Eli Lilly's trial reported average weight loss approaching 30%, with some patients achieving results historically associated with bariatric surgery. A few important caveats Retatrutide approval: FDA status, clinical

DPP-9 belongs to the same family as DPP-4, and it is known that saxagliptin is a less selective inhibitor, whereas sitagliptin is highly selective for DPP-4 (35) and does not alter DPP-9 activity (136)

Physicians may choose to prescribe generic injectable semaglutide for off-label oral use or utilize generic versions in compounding, potentially undermining the premium price of the still-patented oral formulation

Lilly is using its massive income generation (which was roughly $20.6 billion in 2025) to fund a targeted M&A spree

This rebound effect stems from your body's appetite-signaling pathways returning to their pre-treatment state, creating a metabolic cliff that makes weight maintenance challenging without strategic support

L cells express TNF receptor 1 (TNFR1) and chronic exposure to TNF was shown to impair GLP-1 (95) as well as GLP-2 secretion (96)